1. Executive Summary
2. Market Snapshot
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. Business Landscape
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. Technological Outlook
5. Contract Research Organizations (CRO) Services Market By Molecule Type (2021-2031)
5.1. Introduction
5.2. Vaccines
5.3. Cell Gene Therapy
5.4. Others
6. Contract Research Organizations (CRO) Services Market By Type (2021-2031)
6.1. Introduction
6.2. Early Phase Development Services
6.2.1. Preclinical
6.2.2. Toxicology Testing
6.2.3. Discovery Studies
6.2.4. Chemistry, Manufacturing, and Controls
6.2.5. Pharmacokinetics /Pharmacodynamics
6.3. Clinical Research Services
6.3.1. Phase I
6.3.2. Phase II
6.3.3. Phase III
6.3.4. Phase IV
6.3.5. Phase V
6.4. Laboratory Services
6.4.1. Analytical Testing
6.4.2. Bioanalytical Testing
6.4.3. Physical Characterization
6.4.4. Stability Testing, Batch Release Testing
6.4.5. Raw Material Testing
6.4.6. Other Analytical Testing
6.5. Consulting Services
7. Contract Research Organizations (CRO) Services Market By Therapeutic Area (2021-2031)
7.1. Introduction
7.2. Oncology
7.2.1. Breast Cancer
7.2.2. Lung Cancer
7.2.3. Colorectal Cancer
7.2.4. Prostate Cancer
7.2.5. Others
7.3. CNS Disorders
7.3.1. Infectious Diseases
7.3.2. Cardiovascular Diseases
7.3.3. Respiratory Disorders
7.3.4. Diabetes
7.4. Other Therapeutic Areas
8. Contract Research Organizations (CRO) Services Market By End User (2021-2031)
8.1. Introduction
8.2. Pharmaceuticals and Biopharmaceuticals Companies
8.3. Medical Devices Companies
8.4. Academic Institutes
9. Contract Research Organizations (CRO) Services Market By Geography (2021-2031)
9.1. Introduction
9.2. North America
9.2.1. By Molecule Type
9.2.2. By Type
9.2.3. By Therapeutic Area
9.2.4. By End-User
9.2.5. By Country
9.2.5.1. United States
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. South America
9.3.1. By Molecule Type
9.3.2. By Type
9.3.3. By Therapeutic Area
9.3.4. By End-User
9.3.5. By Country
9.3.5.1. Brazil
9.3.5.2. Argentina
9.3.5.3. Others
9.4. Europe
9.4.1. By Molecule Type
9.4.2. By Type
9.4.3. By Therapeutic Area
9.4.4. By End-User
9.4.5. By Country
9.4.5.1. United Kingdom
9.4.5.2. Germany
9.4.5.3. France
9.4.5.4. Spain
9.4.5.5. Others
9.5. Middle East and Africa
9.5.1. By Molecule Type
9.5.2. By Type
9.5.3. By Therapeutic Area
9.5.4. By End-User
9.5.5. By Country
9.5.5.1. Saudi Arabia
9.5.5.2. UAE
9.5.5.3. Israel
9.5.5.4. Others
9.6. Asia Pacific
9.6.1. By Molecule Type
9.6.2. By Type
9.6.3. By Therapeutic Area
9.6.4. By End-User
9.6.5. By Country
9.6.5.1. Japan
9.6.5.2. China
9.6.5.3. India
9.6.5.4. South Korea
9.6.5.5. Indonesia
9.6.5.6. Thailand
9.6.5.7. Taiwan
9.6.5.8. Others
10. Competitive Environment and Analysis
10.1. Major Players and Strategy Analysis
10.2. Market Share Analysis
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Competitive Dashboard
11. Company Profiles
11.1. Thermo Fisher Scientific Inc.
11.2. IQVIA Holdings Inc.
11.3. ICON plc
11.4. Parexel International Corporation
11.5. NAMSA
11.6. Labcorp Holdings Inc.
11.7. WuXi AppTec Co., Ltd.
11.8. Syneos Health, Inc.
11.9. Evotec SE
11.10. Novotech Health Holdings Pte. Ltd.
11.11. CliniExperts Inc.
11.12. PharPoint Research, Inc.
11.13. Veranex
12. Research Methodology
List of Figures
List of Tables